Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer
Young Kwang Chae(Johns Hopkins University), Francis J. Giles(Northwestern University), Sarita Agte(Northwestern University), Wooyoung M. Choi(Northwestern University), Marcelo Cruz(Alliance for Clinical Trials in Oncology), Wade T. Iams(Centerstone), William Han Bae(Northwestern University), Maria Matsangou(Northwestern University), Jonathan F. Anker(Northwestern University), Andrew A. Davis(Northwestern University)
Cited by 43
Related Papers
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
|The Lancet Oncology|2019|537
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
|Journal for ImmunoTherapy of Cancer|2018|468
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|459
Immunotherapeutic approaches for small-cell lung cancer
|Nature Reviews Clinical Oncology|2020|346